Boryung grants Stendhal exclusive rights to Kanarb, novel antihypertensive agent
Published: 2013-07-25 06:59:00
Updated: 2013-07-25 06:59:00
Boryung Pharmaceutical has granted Latin American specialty company Stendhal exclusive commercialization rights for Mexico, Venezuela, Colombia, Perú, Ecuador and most of Central American countries, to its novel antihypertensive drug Kanarb (fimasartan).
Under the terms of the agreement, Stend...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
